Literature DB >> 18025115

Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage.

G Chamilos1, R E Lewis, G Lamaris, T J Walsh, D P Kontoyiannis.   

Abstract

Human polymorphonuclear neutrophils (HPMNs) displayed attenuated hyphal damage associated with impaired O(2)(-) release following exposure to Rhizopus oryzae versus that with Aspergillus fumigatus. Exposure of HPMNs to R. oryzae hyphae resulted in upregulation in Toll-like receptor 2 mRNA and a robust proinflammatory gene expression with rapid (1-h) induction of NF-kappaB pathway-related genes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025115      PMCID: PMC2224765          DOI: 10.1128/AAC.01136-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Neisseria gonorrhoeae porin modifies the oxidative burst of human professional phagocytes.

Authors:  D R Lorenzen; D Günther; J Pandit; T Rudel; E Brandt; T F Meyer
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 2.  Immunity to fungi.

Authors:  Tobias M Hohl; Amariliz Rivera; Eric G Pamer
Journal:  Curr Opin Immunol       Date:  2006-06-12       Impact factor: 7.486

Review 3.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

4.  TLRs govern neutrophil activity in aspergillosis.

Authors:  Silvia Bellocchio; Silvia Moretti; Katia Perruccio; Francesca Fallarino; Silvia Bozza; Claudia Montagnoli; Paolo Mosci; Grayson B Lipford; Lucia Pitzurra; Luigina Romani
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

5.  Activation of respiratory burst in human granulocytes by polychlorinated biphenyls: A structure-activity study.

Authors:  O A Voie; M Tysklind; P L Andersson; F Fonnum
Journal:  Toxicol Appl Pharmacol       Date:  2000-09-01       Impact factor: 4.219

6.  Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens.

Authors:  W C Liles; J E Huang; J A van Burik; R A Bowden; D C Dale
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

7.  Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes.

Authors:  Cristina Gil-Lamaignere; Maria Simitsopoulou; Emmanuel Roilides; Avgi Maloukou; Richard M Winn; Thomas J Walsh
Journal:  J Infect Dis       Date:  2005-02-25       Impact factor: 5.226

8.  Regulation of catalase in Neisseria gonorrhoeae. Effects of oxidant stress and exposure to human neutrophils.

Authors:  H Y Zheng; D J Hassett; K Bean; M S Cohen
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.

Authors:  J C Bowman; P Scott Hicks; M B Kurtz; H Rosen; D M Schmatz; P A Liberator; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanil ide (XTT).

Authors:  T Meshulam; S M Levitz; L Christin; R D Diamond
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

View more
  26 in total

Review 1.  Fungal killing by mammalian phagocytic cells.

Authors:  André Moraes Nicola; Arturo Casadevall; David L Goldman
Journal:  Curr Opin Microbiol       Date:  2008-06-21       Impact factor: 7.934

2.  Predisposing Factors for Mucormycosis in Patients with Diabetes Mellitus; An Experience of 21 Years in Southern Iran.

Authors:  Amene S Sarvestani; Gholamreza Pishdad; Shahram Bolandparvaz
Journal:  Bull Emerg Trauma       Date:  2013-10

Review 3.  Update on mucormycosis pathogenesis.

Authors:  Ashraf S Ibrahim; Dimitrios P Kontoyiannis
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

Review 4.  Pathogenesis of mucormycosis.

Authors:  Ashraf S Ibrahim; Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

5.  Immune responses to Mucorales growth forms: Do we know everything?

Authors:  Emmanuel Roilides; Maria Simitsopoulou
Journal:  Virulence       Date:  2017-09-21       Impact factor: 5.882

6.  Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia.

Authors:  Dimitrios P Kontoyiannis; Sarah P Georgiadou; William G Wierda; Susan Wright; Nathaniel D Albert; Alessandra Ferrajoli; Michael Keating; Russell E Lewis
Journal:  Leuk Lymphoma       Date:  2013-02-20

Review 7.  Challenges in the diagnosis and treatment of mucormycosis.

Authors:  A Skiada; C Lass-Floerl; N Klimko; A Ibrahim; E Roilides; G Petrikkos
Journal:  Med Mycol       Date:  2018-04-01       Impact factor: 4.076

8.  Rhino-orbital-cerebral mucormycosis.

Authors:  Maria N Gamaletsou; Nikolaos V Sipsas; Emmanuel Roilides; Thomas J Walsh
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 9.  Human Fungal Pathogens of Mucorales and Entomophthorales.

Authors:  Leonel Mendoza; Raquel Vilela; Kerstin Voelz; Ashraf S Ibrahim; Kerstin Voigt; Soo Chan Lee
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

10.  Fatal-mixed cutaneous zygomycosis-aspergillosis: a case report.

Authors:  Estelle Cateau; Edouard Randriamalala; Antoine Elsendoorn; Jean-Philippe Giot; Christophe Monegier du Sorbier; Marie-Helene Rodier
Journal:  Mycopathologia       Date:  2013-10-02       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.